CN1150913C - Chinese patent drug for treating peridentitis - Google Patents

Chinese patent drug for treating peridentitis Download PDF

Info

Publication number
CN1150913C
CN1150913C CNB99120283XA CN99120283A CN1150913C CN 1150913 C CN1150913 C CN 1150913C CN B99120283X A CNB99120283X A CN B99120283XA CN 99120283 A CN99120283 A CN 99120283A CN 1150913 C CN1150913 C CN 1150913C
Authority
CN
China
Prior art keywords
chinese patent
patent medicine
skin
radix
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99120283XA
Other languages
Chinese (zh)
Other versions
CN1265916A (en
Inventor
赵扶正
王翠霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB99120283XA priority Critical patent/CN1150913C/en
Publication of CN1265916A publication Critical patent/CN1265916A/en
Application granted granted Critical
Publication of CN1150913C publication Critical patent/CN1150913C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The present invention discloses Chinese patent medicine for treating periodontosis, which uses yangtao actinidia root bark, rhubarb, borneol, cutch and psoralea seed as raw materials and mainly treat periodontosis. When used, the Chinese patent medicine is coated on the affected part; the therapeutic effect is good.

Description

The Chinese patent medicine of treatment periodontal disease
The present invention relates to a kind of Chinese medicine composition, particularly a kind of Chinese patent medicine for the treatment of periodontal disease.
Periodontal disease is one of human general oral disease.Periodontal disease mainly causes because of staphylococcus aureus, Lactobacillus lactis, Streptococcus mutans and bacteroides melanogenicus etc.
Chinese patent CN1190013A discloses a kind of " ointment for toothache and stomatocase ", is made by Cinnabaris, Borax, Rhizoma Coptidis, Radix Et Rhizoma Rhei, Cortex Phellodendri, Radix Glycyrrhizae, Borneolum Syntheticum, Cera Flava, Oleum sesami, cures mainly toothache and stomatocace.
Purpose of the present invention has just provided a kind of Chinese patent medicine for the treatment of periodontal disease, and this Chinese patent medicine has stronger bacteriostasis to the above-mentioned pathogenic bacteria that causes the periodontal disease, and toxic and side effects is little.
Solution of the present invention is based on motherland's medical science to periodontal disease and pathogenetic understanding of relevant odontopathy and Therapeutic Principle, achieve with reference to modern pharmacological research, from motherland's medical treasure-house, filter out and let out gastric heat clearly, reducing swelling and alleviating pain, cooling blood for hemostasis, the convergence granulation promoting, the kidney invigorating teeth consolidating etc., pure Chinese medicine is formulated, by the theory of Chinese medical science prescription, skim the cream off milk, make the local and whole heat-clearing and toxic substances removing that combines of its performance, reducing swelling and alleviating pain, cooling blood for hemostasis, the convergence granulation promoting, the comprehensive therapeutic effect of the kidney invigorating teeth consolidating, reduce the sequela of periodontal disease, delay gingival atrophy, keep tooth firmly healthy, the facilitating digestion function.
The object of the present invention is achieved like this: a kind of Chinese patent medicine for the treatment of periodontal disease, this Chinese medicine are that the drug regimen by following weight parts forms:
Skin 3-9 part Radix Et Rhizoma Rhei 0.5-5 part Borneolum Syntheticum 0.5-4 part of Radix Actinidiae Chinensis
Catechu 0.5-8 part Fructus Psoraleae 0.5-8 part
Optimum weight part of this Chinese patent medicine:
2 parts of 2 parts of Fructus Psoraleaes of 6 parts of Radix Et Rhizoma Rhei of the skin of Radix Actinidiae Chinensis, 2 parts of Borneolum Syntheticums, 2 share tea
Optimum weight part of this Chinese patent medicine:
1 part of 1 part of Fructus Psoraleae of 5 parts of Radix Et Rhizoma Rhei of the skin of Radix Actinidiae Chinensis, 3 parts of Borneolum Syntheticums, 2 share tea
Chinese patent medicine of the present invention is good to the bactericidal effect of the main pathogenic bacteria that causes the periodontal disease, and toxic and side effects is little.
Preparation method of the present invention:
Earlier Radix Et Rhizoma Rhei is made Radix et Rhizoma Rhei (stir-fried with wine) by the Chinese medicine processing method, then Radix et Rhizoma Rhei (stir-fried with wine) is crushed to 120 orders, Borneolum Syntheticum is ground into 120 orders, Radix Actinidiae Chinensis is cleaned, got its skin, oven dry and the corium farinosum of Radix Actinidiae Chinensis is broken to 120 orders, Fructus Psoraleae is removed impurity, mix thoroughly, run through with 2% saline solution, take out airing, pulverize 120 orders, catechu is pulverized ground to 120 orders, mix homogeneously.
Using method of the present invention:
Earlier patient's tooth, teeth space are cleaned, then medicine of the present invention is applied to by treatment periodontal place, mouth included about 20 minutes, swallowed, and was coated with 0.1-0.2g, every day 3-6 time at every turn.
The acute toxicity test of this Chinese patent medicine is as follows:
One experiment material
Animal: Kunming mouse male and female half and half, body weight 20.0 ± 2.0g is bought by Lanzhou Institute of Biological Products, the animal quality certification number: the general GAC001 of Gansu Province's laboratory animal administration commission (96).
Medicine: it is standby that this Chinese patent medicine grinds the preparation variable concentrations with distilled water.
Method
Mtd test
20 of mices, male and female half and half, in testing the previous day, water is can't help in fasting overnight, under the condition of 20 ± 2 ℃ of room temperatures, gastric infusion twice in 24 hours, drug level is 0.33g/kg, (Cmax) 0.8ml/20g, (maximum volume), dosage is 13.2g/kg, observes a week after the administration.
Mice in 30 minutes, because the administration volume is bigger than normal, has discomfort slightly after administration as a result, and it shows as mice and has loose bowels, back of a bow phenomenon recovers normal subsequently rapidly, and comparatively quiet, observes continuously 15 days, mice all survives, and cuts open inspection, the careful main inner internal organs of perusal, no abnormality seen.
Brief summary
Replenish to require (1) according to new drug (Chinese medicine) toxicological study, can accept maximum volume under the Cmax, carry out the maximum tolerated dose experiment mice.The mice dosage is 13.2g/kg as a result, is 660 times of clinical maximum dosage (0.02g/kg), and overt toxicity is not seen in all survivals in the observation period, shows that this poison of drug is less, and is clinical safe in utilization.
List of references
(1) Ministry of Public Health " provisions for new drugs approval " three, new drug (Chinese medicine) pharmacology, the technique complementary explanation of toxicological study.
Two are subjected to the reagent thing
Title: the Chinese patent medicine specification 4-4.5g/ bottle of this invention
Compound method: take by weighing the Chinese patent medicine of an amount of this invention, be mixed with pasty state with distilled water and get final product.
Positive control: periodontal is clear, is provided by Gansu Lan Pu pharmaceutcal corporation, Ltd, uses for animal skin hypersensitive test positive control.
Animal:
1, Japanese white big ear rabbit, body weight 2.5 ± 0.2kg, Cavia porcellus 250 ± 20g plants in Britain, and male and female half and half are bought by Lanzhou Institute of Biological Products, the laboratory animal quality certification number, Gansu Province's laboratory animal administration commission 001.
2, the Animal Lab. quality certification number, Gansu Province's laboratory animal administration commission 004.
| experimental technique and result |
1, skin acute toxicity test
Select 12 of rabbit, in administration spinal column left and right sides depilation in preceding 24 hours, area is 15cm 2Be divided into 3 groups at random, i.e. intact skin, negative control group, behind damaged skin group and the negative control group right side skin degerming, draw the well word gently with aseptic syringe needle,, press the 1g/kg administration to scratch skin oozing of blood degree of being, this dosage is equivalent to 50 times of clinical consumption, the lake agent evenly is applied in depilation district, right side, and the negative control left and right sides is evenly smeared distilled water, observes the whole body poisoning situation of rabbit every day.
The result observes all interior administration groups continuously searches for food, breathe, and activity, body weight is normal, depilation district skin, eyes, oral cavity sticking to mould no abnormality seen.Damaged skin is formed a scab rapidly, and none animal dead cuts open the careful macroscopy of inspection main organs, does not see obvious pathological changes.
Above result shows that this product is lower to animal skin toxicity.
2, skin irritation test
Select 12 of rabbit, animal depilation, grouping, the skin injury mode is the same, and drug paste evenly is applied in two groups of administration depilation districts, and drug level is the 0.6g/kg administration, be equivalent to 30 times of clinical dosage, once a day, continuous three days, matched group is smeared distilled water, smears the back every day and sees and to look into skin conditions, after the last administration 1, saw the skin irritation degree of looking in 24,48,72 hours, press table 1,2 pairs of skin irritation reactions are marked and the stimulus intensity evaluation, and scoring sees Table 3.
Table 3 is the result show: by the skin irritation intensity evaluation, this product contacts equal nonirritant to intact skin.
3, skin allergy experiment
Select 30 of Cavia porcelluss, white, both sides depilation 3.3cm 2, be divided into 3 groups, i.e. this Chinese patent medicine administration group sensitization, booster dose is 0.4g/kg, is equivalent to 20 times of clinical dosages, the clear positive controls of periodontal (make pasty state equally, smearing the depilation district), distilled water negative control group.In the 0th, 7,14 days left side sensitization contact 0.1g/ml, 1ml/ only, after last sensitization 14 days, the right side excited contact, 1ml/, promptly considerable looking into, and in 24, saw in 48,72 hours again and look into the anaphylaxis situation, the skin allergy standards of grading see Table 4, tried the thing reaction property with judgement, the reaction meansigma methods is that erythema forms total points divided by adding up to number of animals, carries out sensitivity response intensity par by table 5, and the sensitization rate is that the routine number of skin erythema or edema animal is divided by the animal subject sum in the table.The results are shown in Table 6.
The result shows that this Chinese patent medicine is weak sensitization to guinea pig skin.
Conclusion
This product carries out animal skin toxicity with reference to pertinent regulations in the specification requirement of new drug toxicity, stimulates, and hypersensitive test, experimental result show, and is complete lower with damaged skin toxicity to rabbit, to the skin nonirritant, guinea pig skin is weak sensitization.
List of references
Clinical research guideline compilation, bureau of drug administration of Ministry of Health of the People's Republic of China.
Table 1 skin irritation reaction scoring
The irritant reaction score value
Erythema
No erythema 0
Inadequate visible 1
In strong erythema 2
Serious erythema 3
The aubergine erythema also has eschar to form 4
Edema
No edema 0
Inadequate visible 1
Cutaneous protuberance profile clear 2
Edema about 1mm of protuberance and expanded range 3
Table 2 skin irritation intensity evaluation
The intensity score value
Nonirritant<0.5
Slight zest<2.09
Moderate zest<6.0
Intensity zest<6.0
Table 3 Chinese patent medicine of the present invention is smeared the skin irritation test appraisal result
The group rabbit is counted erythema and forms score value edema formation score value total points
Intact skin administration group 4000
Matched group 4000
Damaged skin administration group 4 0.2 0 0.2
Matched group 4000
Table 4 skin allergy standards of grading
The dermoreaction score value
No erythema forms 0
Slight erythema 1
Moderate erythema 2
Severe erythema 3
Edematous erythema 4
The classification of table 5 sensitization rate
Sensitization rate (%) response strength
The weak sensitization of 0-10
The slight sensitization of 20-30
40-60 moderate sensitization
70-80 height sensitization
The high degree sensitization of 90-100
Each treated animal sensitization rate of table 6
Group anaphylaxis mean scores X sensitization rate %
This Chinese patent medicine group 00
The clear group 2.5 100 of periodontal
Distilled water group 00
The external bacteriostatic experiment of this Chinese patent medicine is as follows:
One, experiment material
1.1 the medicinal liquid preparation takes by weighing this Chinese patent medicine 5g, adds 50 milliliters in water, soaks 2 hours, boils 10 minutes, filters, filtrate is after 8 pounds of sterilizations of flowing steam, and is standby.
1.2 strain staphylococcus aureus (26003), Lactobacillus lactis over sixty years of age (34102), Streptococcus mutans (32471) and bacteroides melanogenicus provide by Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
1.3 the culture medium Nutrient agar, sulfur ethylate agar culture medium.The increase liquid of detesting bacteria is to add chlorhematin (5ug/ml) in thioglycollate solution medium, adds NaOH (1mg/ml) before the sterilization, faces with preceding adding vitamin K1 (0.1ug/ml).Detest the bacteria diluent for containing the brucella broth of 5%Filches Digestive system and vitamin K1 (0.1UG/Ml).
1.4 bacteria suspension is got bacterium platform-oese on the inclined working in the corresponding liquid culture medium, needs 37 hours with dilution meat soup, makes the bacteria suspension that becomes to give prominence to 10cfu/ml.
Two, experimental technique and result
2.1 method experimentizes by the liquid doubling dilution, add bacteria suspension 0.1ml in each pipe, cultivated 24.8 hours in 37 degree, the least concentration that can not grow with antibacterial is minimum antibacterial dense (N2C), is minimum bactericidal concentration (N2C) with least concentration that can killing bacteria.
2.2 the results are shown in Table 7 and table 8
Three conclusions
Periodontal disease mainly shows as gingival swelling and pain, chews pain, periodontal pocket formation and gingiva pyorrhea etc.This Chinese patent medicine all has stronger bacteriostasis external to several pathogenic bacterias that cause periodontal disease, so this Chinese patent medicine has therapeutical effect to the various microbial periodontal disease of causing a disease.
List of references
Clinical research guideline compilation, bureau of drug administration of Ministry of Health of the People's Republic of China.
Surplus he medical hygiene thing is learned People's Health Publisher 1,983 235 251
Precious medicine microbiology of Zheng Jun a large bell Wang Guang and inspection technology People's Health Publisher 1,989 349 353
This Chinese patent medicine of table 7 is to the minimum bacteriostatic experiment (g/100ml) of pathogenic bacterium
Concentration 5 2.5 1.25 0.625 0.312 0.16 0.8 0.4
Staphylococcus aureus----++++
Over sixty years of age Lactobacillus lactis----++++
Bacteroides melanogenicus-----+++
Streptococcus mutans----++++
Annotate: "+" expression has bacteria growing
"-" expression asepsis growth
This Chinese patent medicine of table 8 is to the minimum bactericidal experiment (g/100ml) of pathogenic bacterium
Concentration 5 2.5 1.25 0.625 0.312 0.16 0.8 0.4
Staphylococcus aureus---+++++
Over sixty years of age Lactobacillus lactis----++++
Bacteroides melanogenicus---+++++
Streptococcus mutans---+++++
Annotate: "+" expression has bacteria growing
"-" expression asepsis growth
Embodiment
Earlier Radix Et Rhizoma Rhei is made Radix et Rhizoma Rhei (stir-fried with wine) by the Chinese medicine processing method, then Radix et Rhizoma Rhei (stir-fried with wine) is crushed to 120 orders, Borneolum Syntheticum is ground into 120 orders, Radix Actinidiae Chinensis is cleaned, got its skin, oven dry and the corium farinosum of Radix Actinidiae Chinensis is broken to 120 orders, Fructus Psoraleae is removed impurity, mix thoroughly, run through, take out airing with 2% saline solution, pulverize 120 orders, catechu is pulverized ground to 120 orders.
Take by weighing skin 6kg, Radix Et Rhizoma Rhei 2kg, Borneolum Syntheticum 2kg, catechu 2kg, the Fructus Psoraleae 2kg of the Radix Actinidiae Chinensis that processes, and with each flavor raw material of Chinese medicine mix homogeneously.

Claims (3)

1. Chinese patent medicine for the treatment of periodontal disease is characterized in that this Chinese patent medicine is to be made by following raw medicaments in portion by weight:
Skin 3-9 part Radix Et Rhizoma Rhei 0.5-5 part Borneolum Syntheticum 0.5-4 part of Radix Actinidiae Chinensis
Catechu 0.5-8 part Fructus Psoraleae 0.5-8 part.
2. according to the Chinese patent medicine described in the claim 1, it is characterized in that the weight portion of the crude drug of this Chinese patent medicine:
2 parts of 2 parts of Fructus Psoraleaes of 6 parts of Radix Et Rhizoma Rhei of the skin of Radix Actinidiae Chinensis, 2 parts of Borneolum Syntheticums, 2 share tea.
3. according to the Chinese patent medicine described in the claim 1, it is characterized in that the weight portion of the crude drug of this Chinese patent medicine:
1 part of 1 part of Fructus Psoraleae of 5 parts of Radix Et Rhizoma Rhei of the skin of Radix Actinidiae Chinensis, 3 parts of Borneolum Syntheticums, 2 share tea.
CNB99120283XA 1999-10-09 1999-10-09 Chinese patent drug for treating peridentitis Expired - Fee Related CN1150913C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB99120283XA CN1150913C (en) 1999-10-09 1999-10-09 Chinese patent drug for treating peridentitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB99120283XA CN1150913C (en) 1999-10-09 1999-10-09 Chinese patent drug for treating peridentitis

Publications (2)

Publication Number Publication Date
CN1265916A CN1265916A (en) 2000-09-13
CN1150913C true CN1150913C (en) 2004-05-26

Family

ID=5281460

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB99120283XA Expired - Fee Related CN1150913C (en) 1999-10-09 1999-10-09 Chinese patent drug for treating peridentitis

Country Status (1)

Country Link
CN (1) CN1150913C (en)

Also Published As

Publication number Publication date
CN1265916A (en) 2000-09-13

Similar Documents

Publication Publication Date Title
CN1119154C (en) Live triple bifidobacteria preparation and preparing method thereof
CN1883275A (en) A botanical antibiotic and application thereof
CN101053568A (en) Compound and its processing technology for compound sulfamonomethoxine sodium injection
CN111297961A (en) Dong medicine for promoting wound healing
WO2005012503A1 (en) Novel lactobacillus, living body activating lactobacillus preparation and preventive or therapeutic agent against living body infection
CN102100687B (en) Application of medicine composition with function of exterminating oral helicobacter pylori
CN1150913C (en) Chinese patent drug for treating peridentitis
CN1903254A (en) Compound medicine for treating wind-heat type cold and preparing method thereof
CN1302785C (en) Health-care medicinal composition, and preparing method and use thereof
CN109224024A (en) For preventing and treating the pharmaceutical composition and its application method of fresh-water fishes bacteria mixed infection
CN1281228C (en) Medicine for hyperplasia of mammary glands and its preparation
CN108378103A (en) A kind of preventing decayed tooth ready-to-eat food
CN101053657A (en) External applied preparations for treating intractable skin ulcer
CN1177637A (en) Preparation of living bacillus subtilis and preparation method thereof
CN1193779C (en) Vagina cleaning and antiphlogistic suppository and its preparing method
CN112741869A (en) Fermented traditional Chinese medicine preparation for strengthening body resistance and eliminating pathogenic factors of livestock and poultry and preparation method thereof
CN1215595A (en) External use medicine for treating soft tissue injury and its producing method
CN101461850B (en) Application of Chinese medicinal composition in preparing medicament for treating acne
CN1299684C (en) Aquatic animal antibacterial agent and preparation method thereof
CN1164278C (en) Biological preparation for treating burn and preparation method thereof
CN109172649A (en) A kind of application of Chinese medicine composition in the drug that preparation prevents and treats Streptococcus suis
CN1220515C (en) Medicine for treating throat disease
CN107494922A (en) It is a kind of to be used to adjust Tiny ecosystem Chinese herbal feed additive of enteron aisle and preparation method thereof
CN1954835A (en) Sea-buckthorn plant preparation and its preparation method
CN1224418C (en) Biological preparation containing marine active substance and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee